VANCOUVER, British Columbia--(BUSINESS WIRE)--Variational AI, the company behind Enki™, an advanced foundation model for small molecule drug discovery, today announced the completion of its ...

Yes! I want to get the latest chemistry news from C&EN in my inbox every week. ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly ...

Variational autoencoders are primarily used ... Transformers and diffusion-based models like AlphaFold and DiffDock accelerate drug discovery, enabling de-novo compound generation.

Variational AI is at the forefront of Artificial Intelligence drug discovery and we look towards a successful and lasting partnership. Our unique Enki™ Platform is the first commercially accessible ...

Variational’s Enki technology is a drug discovery spin on an idea that will be familiar to anyone who has used a generative AI platform. In a similar way to how AI software like DALL-E and ...

"Great drugs start with great molecules, but most drug discovery begins in the same place – screening molecular libraries or tweaking existing scaffolds," said Handol Kim, CEO of Variational AI.

Variational AI, the company behind Enki™, an advanced foundation model for small molecule drug discovery, today announced the completion of its oversubscribed $US5 ...